AKCEA THERAPEUTICS

Catalyst Pharmaceuticals Appoints Dr. William Andrews as Chief Medical Officer to Lead Rare Disease Strategy

- Catalyst Pharmaceuticals appointed Dr. William T. Andrews as Chief Medical Officer, succeeding retiring Dr. Gary Ingenito after his successful 10-year tenure with the company. - Dr. Andrews brings 24 years of global biopharmaceutical experience with 18 years specifically focused on rare diseases, having previously served as CMO at multiple biotech companies. - The leadership change coincides with strong financial performance, including a 13% stock price increase over the last quarter and 443.67% total return over five years. - The appointment aims to strengthen Catalyst's strategic direction in rare diseases and support continued growth of key products AGAMREE and FIRDAPSE.